Immunovant, Inc. (IMVT)
NASDAQ: IMVT · IEX Real-Time Price · USD
27.97
-0.44 (-1.55%)
At close: Jul 19, 2024, 4:00 PM
27.91
-0.06 (-0.21%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Immunovant Employees
Immunovant had 207 employees as of March 31, 2024. The number of employees increased by 43 or 26.22% compared to the previous year.
Employees
207
Change (1Y)
43
Growth (1Y)
26.22%
Revenue / Employee
n/a
Profits / Employee
-$1,252,831
Market Cap
4.09B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 207 | 43 | 26.22% |
Mar 31, 2023 | 164 | 40 | 32.26% |
Mar 31, 2022 | 124 | 56 | 82.35% |
Mar 31, 2021 | 68 | 26 | 61.90% |
Mar 31, 2020 | 42 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Integer Holdings | 10,500 |
Perrigo Company | 9,140 |
Alkermes | 2,100 |
Ultragenyx Pharmaceutical | 1,276 |
Inspire Medical Systems | 1,011 |
ImmunityBio | 628 |
Axsome Therapeutics | 545 |
Crinetics Pharmaceuticals | 290 |
IMVT News
- 7 weeks ago - Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 - GlobeNewsWire
- 4 months ago - Immunovant Awarded U.S. Patent for IMVT-1402 - GlobeNewsWire
- 5 months ago - Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 - GlobeNewsWire
- 7 months ago - Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 7 months ago - Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease - GlobeNewsWire
- 7 months ago - Best Small-Cap Stocks to Buy for 2024 and Beyond - Kiplinger
- 8 months ago - Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential - GlobeNewsWire
- 8 months ago - Immunovant to Present at Upcoming Investor Conferences - GlobeNewsWire